在 HPV16 诱导的口咽鳞状细胞癌 (OPSCC) 中检测到肿瘤浸润 HPV16-E2 特异性 CD8 T 细胞。肿瘤内 CD4 T 细胞是否针对 HPV16 E2，以及 HPV16-E2 特异性免疫是否有助于更好的临床结果尚不清楚。在前瞻性 HPV16 OPSCC 队列中，我们定期检测 HPV16-E2 特异性 CD4 和 CD8 瘤内 T 细胞，尽管频率低于共同浸润的 HPV16-E6/E7 特异性 T 细胞。这些 HPV16 反应性 T 细胞在激活时会产生多种细胞因子，这表明它们具有多功能性。重要的是，它们在肿瘤内的联合存在预示着更高的生存率，强调了 HPV16-E2 特异性 T 细胞在抗肿瘤免疫中的价值，并建议将其用作免疫治疗的靶抗原。版权所有 © 2023 作者。由爱思唯尔公司出版。保留所有权利。

Tumor-infiltrating HPV16-E2-specific CD8+ T cells have been detected in HPV16-induced oropharyngeal squamous cell carcinoma (OPSCC). Whether intratumoral CD4+ T cells target HPV16 E2 and if HPV16-E2-specific immunity contributes to better clinical outcome is unknown. In a prospective HPV16+ OPSCC cohort, we regularly detect HPV16-E2-specific CD4+ and CD8+ intratumoral T cells, albeit at lower frequencies than the co-infiltrating HPV16-E6/E7-specific T cells. These HPV16-reactive T cells produce multiple cytokines when activated, indicating their polyfunctionality. Importantly, their combined intratumoral presence predicts superior survival, emphasizing the value of HPV16-E2-specific T cells in anti-tumor immunity and suggests its use as a target antigen for immunotherapy.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.